MITHRACIN Drug Patent Profile
✉ Email this page to a colleague
When do Mithracin patents expire, and what generic alternatives are available?
Mithracin is a drug marketed by Pfizer and is included in one NDA.
The generic ingredient in MITHRACIN is plicamycin. There is one drug master file entry for this compound. Additional details are available on the plicamycin profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for MITHRACIN?
- What are the global sales for MITHRACIN?
- What is Average Wholesale Price for MITHRACIN?
Summary for MITHRACIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 25 |
| Clinical Trials: | 1 |
| Patent Applications: | 4,935 |
| DailyMed Link: | MITHRACIN at DailyMed |
Recent Clinical Trials for MITHRACIN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Cancer Institute (NCI) | Phase 2 |
US Patents and Regulatory Information for MITHRACIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer | MITHRACIN | plicamycin | INJECTABLE;INJECTION | 050109-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
